In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Gil Roth, President of the Pharma & Biopharma Outsourcing Association (PBOA).

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Gil, covering:

• The evolution of the PBOA over the last decade, the impact of M&A on the Association, and building a safe place where CDMOs belong
• How the industry has evolved over the last few years after Covid, including harder times and areas of green shoots
• Why Gil believes Novo's purchase of Catalent is a black swan event and not a new megatrend
• A deeper dive into fine details of The BIOSECURE Act, and its potential impact on the CDMO space over the next 7-8 years
• The need to know market headwinds and tailwinds that you simply cannot ignore

Gil Roth is the Founder and President of the Pharma & Biopharma Outsourcing Association (PBOA), a nonprofit trade group that advocates for the regulatory, legislative and general business interests of the CMO/CDMO sector. In this role, he brings CDMO perspectives and education to FDA, the US Congress, and other bodies, and brings CDMOs together to share best practices, develop policy positions, and provide briefings on government positions that impact that sector. He also organizes and hosts PBOA's annual members-only Meeting & Conference.

Previously, he was the Founding Editor of Contract Pharma magazine. In his alleged free time, he produces a weekly cultural conversation podcast called the Virtual Memories Show (https://chimeraobscura.com/vm)

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Steven Chevillotte, Chief Executive Officer at SaniSure.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Steven, covering:

• Building a great partner through professionalization and integration while retaining founder DNA of entrepreneurship and innovation
• The transformation of quality components and complex assemblies to game changing systems and solutions
• How SaniSure differentiates from smaller and larger bioprocessing organizations
• Why exceptionally robust and clean products coupled with excellence in customized components and designing flow paths make SaniSure the partner of choice for Advanced Therapies (Eg: Cell Therapy)
• Making the bioprocessing supply chain more robust

SaniSure CEO Steven has held senior leadership roles in finance, operations, and general management at precision manufacturing businesses, always in highly engineered and highly regulated industries, including Class III Medical Devices and Aerospace & Defense. Has learned best practices at large public and private companies and has developed an expertise and passion for hands-on transformation through strategy deployment. He is experienced with M&A and integration in PE-backed environments and has led a successful exit process. Steve holds Masters degrees in Manufacturing Systems Engineering and Financial Analysis & Accountancy.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping comp

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Andy Holt, CCO of Viralgen Vector Core.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Andy, covering:

• Growing a CDMO while dealmaking in a gene therapy company…at the same time
• Selling a revenue-generating therapy company to Bayer during the pandemic
• Faster failure or faster acceleration; the need to celebrate every gene therapy batch as it’s going to save lives
• The challenges of manufacturing AAV gene therapies and why the next generation of CGT CDMOs need a voice at the table 

Andy has been working on the business side of cell and gene therapy for more than 15 years, focused on creatively connecting science and solutions, whether health care for whale sharks or supporting multi-billion dollar transactions between biotech and big pharma. 

Along the way, he has held positions in business development and management for several large CDMOs like Lonza and MilliporeSigma, leadership positions in Askbio, Ncardia, and Cellistic, and his current role as Chief Commercial Officer for Viralgen, a pioneering AAV-focused CDMO leveraging Askbio’s manufacturing expertise for clients around the world.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency that helps companies differentiate, get noticed, and grow in the life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Adrienne Leussa, Director of Ecosystem Partnerships at 54gene.Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adrienne, covering:

• How the reality of the health challenges living in Africa as a child drove Adrienne into the drug discovery space.
• A rich insight into the only remaining high growth market globally for pharma companies.
• Learn about the main cities driving drug development growth within Africa and the prospect for more localised manufacturing.
• Life working for one of the leading biotech companies in Africa.
• Living life by curiosity as an ethos to make a lasting impact in the world.

Adrienne is a Biochemist (PhD) with 10+ years of hands-on experience and a plethora of diverse technical skills within the area of drug discovery and development. She has also worked as a lecturer and researcher in top African universities helping inspire a generation of scientists through access to information on the applications of biotechnology.She is fluent in 3 of the most used languages in Africa: Portuguese, French and English, and is ardent about continued learning, cross-culture collaboration, problem solving, customer service and mentoring.Adrienne’s mission is to elevate Africa through high quality, innovative, and credible scientific output for global prosperity.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with David Enloe, President and CEO at Societal™ CDMO. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with David, covering:

• Being at the birth of viral vectors and the-infant gene therapy field in the 90s... but choosing not to be there today. 
• After a career spent all over the world - he shares his pearls of wisdom of what he’s learnt from a lifetime of international business.
• Navigating business confusion and redefining companies from the inside out, while focusing on people and patients.
• Being a humble, humane, empathetic leader that does not take himself too seriously... and makes decisions quickly.
• Uncertainty around the capital markets and what this means to the CDMO space in terms of potential headwinds.

David has over two decades of executive leadership experience in biotechnology, clinical drug development, and GMP manufacturing.He was CEO at Ajinomoto Bio-Pharma Services, CEO at Althea CMO and also served as head of Lonza’s Viral Therapeutics Business Unit, which resulted from Lonza’s acquisition of Vivante GMP Solutions. Prior to that, he spent 14 years with a biotech company, Introgen Therapeutics, and played an integral part in taking the company through a successful IPO in 2020.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Ata Tuna Ciftlik CEO at Lunaphore.Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ata, covering:

• Bringing the next generation ‘satellite for tumours’ sequencing tools for immuno oncology and cancer research to drug discovery, and eventually the mainstream.
• Why life science start-ups need data to survive and thrive. And key lessons of entrepreneurship, from theory to reality.
• The avalanche effect - from a 2.5k competition fundraise to $50m in a market on-track to become $10b.
• Unmissable leadership lessons from PhD-start up to global life science business.

Ata Tuna Ciftlik was born in Ankara, Turkey. He received a double-B.Sc in Mathematics and Electronics Engineering from Middle East Technical University (METU) in 2006. He started interdisciplinary research at the interface of Microfluidics and Biology during his MSc studies in METU, where he received thesis of the year 2009 prize.

Next, he obtained interdisciplinary PhD in Biomedical Microfluidic Systems from Swiss Institute of Technology in Lausanne (EPFL) and was awarded internationally known Dimitris N. Chorafas foundation prize in the category of cutting egde technology.After inventing its core technology during his PhD, he has co-founded Lunaphore in 2014.

Lunaphore so far received USD 60 million financing from private and public sources, lead multiple innovation projects in Switzerland and Europe, counts close to 100 people, appeared more than 100 times in national and international media channels, claimed 22 awards and has consistently been selected as one of the best start-ups in the country. Ata Tuna is married, has 2 children and enjoys biking, running and hiking.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this special one-off episode of Molecule to Market, your host Raman Sehgal embarks on a solo cast to cover some of the major supply chain themes uncovered through Molecule to Market interviews. The insights were originally delivered live on stage at CPhI North America 2022. Whether you’re a CDMO, CPO, drug sponsor or equipment vendor - this is not to be missed.Your host, Raman, covers:

• 4 main challenges the sector has felt over the last two years 
• 4 solutions we are seeing and that you may want to think about
• 4 trends you need to know for your business

Along with being the host of Molecule to Market, Raman Sehgal is the founder of PE-backed ramarketing, co-founder of Lead Candidate, and best-selling author of The Floundering Founder.Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who discusses the pharmaceutical and biotechnology supply chain live from CPhI North America 2022, with:

• Robert Lee, President at Lubrizol Life Science Health - CDMO Division at The Lubrizol Corporation
• Lauren (Naughton) Hanna, Publisher at Contract Pharma
• Bob Macadangdang, Client Development Manager at Sharp, Contract Pharmaceutical Packaging
• Stephen Houldsworth, VP, Global Head of Platform Management & Marketing - Corden Pharma International
• Claire Robinson, Partnership Manager at Sterling Pharma Solutions

What are the biggest challenges in our space? What are the latest trends? What should you be aware of? Listen and find out what our guests think!

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Adam Wilson, President - BioPharmGuy. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adam, covering:

• The humble start-up story and journey of the biopharmguy.
• The pivot that took the website from being a job sharing site to one of the most widely-regarded and used platforms in the biotech world.
• The value of simply focussing on looking after your product as your fundamental market differentiator.
• Poking fun at the sector and being a source of entertainment as well as information.

Adam is the BioPharmGuy. Prior to running BioPharmGuy full-time, he worked as a Process Development Engineer at a public biotech, an FDA Investigator and a Lab Tech in a dermatology research lab at a nonprofit hospital. His various experiences have contributed to his knowledge of the biotech industry which has enabled BioPharmGuy to become the best biotech company directory in existence. He independently created and built BioPharmGuy.com which now receives 40,000+ unique visitors every month.

The website built around a database of information on biotech, pharmaceutical, medical device and life science companies around the world. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed. Your host Raman Sehgal is the author of The Floundering Founder.

Event season is truly well on its way and where better to start than Swiss Biotech Day, the leading biotechnology conference in Switzerland. Renowned for its innovative biotech start-ups and big pharma companies all in attendance, it was a great chance to meet experts from the life science industry from across Europe. Which is why it should come as no surprise that your host Raman Sehgal brought Molecule to market once more to the event space.

If you loved the ‘Memoir of DCAT 2022’ episode, this is a pod for you as he hit the event space again in style and interviewed some more great guests along the way. Listen to a diverse range of our guests’ thoughts during this event.

• Richard Collins, Managing Director Bio2Business Ltd
• Hanns-Christian Mahler, CEO at ten23 health
• Stefano Console, Founder & Senior Advisor at Oriento SA
• Philippe Tschopp, Head of Business Development CDMO Glatt

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Terry Novak, President & Chief Executive Officer at Salubrent Pharma Solutions. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Terry, covering:

• What he has learnt from 40 years in the pharma, biopharma and contract services space
• The best marketing technique - communicating constantly to your internal audience.
• The wave of orphan drugs that are driving demand for small scale and flexible manufacturing capabilities.
• How a focus on talent is going to make or break companies in the next 3-5 years.

Terry has extensive CDMO C-suite execution experience serving in numerous capacities. Terry has served on the Board of Directors of Pernix Therapeutics Ireland, Percivia LLC, American Red Cross Northern NJ Division, Patheon Puerto Rico, Frontline Pharmaceuticals, Curaxis Pharmaceuticals and is currently on the Board of Directors of Salubrent Pharma Services and Minutemen Life Sciences. Operationally, Terry has served as the CEO of Tedor Pharmaceuticals, COO of Pernix Pharma, President of Norwich Pharmaceuticals, President of Patheon North America, President of Frontline Pharmaceuticals and President of DSM.

During his 40 years in industry, he had built a track record of rapid turn-around success includes achieving consistent double-digit growth in revenues and EBITDA.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Michael Kallelis, Chief Executive Officer at Mikart.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mike, covering:

• Growing up, studying and forging a career in Boston during the volatile biotech boom in Massachusetts.
• His hard-earned 40-years playbook of how to rebuild and revitalise a family owned business by respecting, studying and redirecting efforts.
• An insight into the under the radar but explosively vibrant life science scene in Atlanta, GA
• The role of a mid-market CDMO to drug development companies.
• The phenomenon hitting the North America healthcare market that you need to be aware of as it will impact CDMOs in the small molecule space...

Michael Kallelis has spent his career in public and private life science companies where he has successfully implemented commercial and operational growth strategies. Prior to Mikart, he held several senior roles including president of Exiqon Inc., co-founder and chief operating officer of Boston Biosystems, vice president of business development at KMC Systems, and general manager of several GE Healthcare businesses. 

His experience covers a range of technologies, including radiopharmaceuticals, gene expression analysis, medical devices, automated laboratory systems, oligonucleotides, specialty chemicals, biologics, and small molecules. Mike has been the CEO at Mikart since the fall of 2018.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Ray Kaczmarek, Chief Executive Officer at Genezen. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ray, covering:

• Translating military life lessons into key business leadership - taking care of your people, having operational discipline and allowing people to be leaders.
• Invaluable learnings from taking a drug from clinical trials to commercial and on-market supply.
• Insight into the booming cell and gene therapy space and how it will change the way we view medicine as a cure, not a treatment.
• The under the radar, up and coming region of Fishers, Indianapolis. Could this be the next big life science hub?

Genezen CEO Ray has over 25 years of leadership experience with the past 20 years in biotechnology and pharmaceutical operations. Ray has previously held positions including President at Nitto Avecia Pharma Services, Founder OC Biotech Consultants, SVP of GMP Operations at TriLink BioTechnologies, and VP of Manufacturing and Supply Chain Operations at Pacira Biosciences. He has supported new drug development, clinical operations, and commercial operations in biologics, vaccines, and pharmaceuticals throughout his career. Ray leads Genezen’s growth strategy and is focused on finding ways to achieve excellence for our employees, our clients, and their patients.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mark W. Womack, Chief Executive Officer at BioCina.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mark, covering:

• How a tough upbringing in LA led him to the US Navy, and then onto a pathway into leadership
• Why he decided to end his own practice and jump into a senior role within a biopharma CDMO space
• The key factors that led him to relocate to Adelaide, Australia
• The reality that most biologics CDMOs frequently fail to deliver... and why winning requires operating with discipline, and consistently executing at a high level

Mark W. Womack is BioCina’s Chief Executive Officer. Prior to BioCina, he was CEO of KBI Biopharma and Selexis SA, and previous to that, he was CEO and Managing Director of Stelis Biopharma, leading both to significant YOY growth. Preceding Stelis, as the CBO for AGC Biologics, one of the world’s leading global biopharma CDMOs, he led them to nearly a 300% increase in new sales in just two years.

Prior to joining AGC Biologics, Mark served over 20 years as an international management consulting industry leader, guiding many of the world’s renowned companies to achieve record highs in revenue and profit. This included a $20B post-merger integration within General Motors and numerous transformations that generated more than $100M in certified client benefits.

Mark began his professional journey by leading a succession of U.S. Navy units to unprecedented results, including while serving as a combat center leader on a destroyer class ship, and he received numerous of the Navy’s highest honors and awards.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Hans J Johansson, Global Applications Director at Purolite. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Hans, covering:

• A career spent developing ideas and creating products that produce new applications for customers and commercial success.
• Driving the Purolite business unit from the ground-up from a lab bench to a commercial scale life science based franchise.
• Hans’ lifelong habits and approach that have enabled him to have a successful career.
• An insight into Sweden’s vibrant life science hub - Uppsala.
• The development of new technologies that will increase yield while reducing environmental footprint... a sign of things to come!

Hans J Johansson is Global Applications Director at Purolite Life Sciences, Llantrisant, Wales. He has spent more than 30 years in the Biotech industry. Most of the time in research and development at Pharmacia/Amersham/GE Healthcare with a special focus on design and applications of industrial chromatography resins intended for antibody purification. He frequently publishes in scientific journals and is the holder of more than ten patents around resin design and large-scale protein purification. He is currently working with development and applications of novel, agarose-based, chromatography resins.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jim Hall, President at Lifecore Biomedical

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jim, covering: 

• What a period working on the sponsor/buyer side taught him about getting best out of your CROs and CDMOs

• The challenges of doubling in size twice in just 10 years and not getting ‘too far out over your skis’
• Building a culture with longevity and not losing sight of the purpose - never hurting a patient
• Insight into market growth figures and why the injectable market remains a hot spot
• Timeless advice around not chasing the money, always be learning and keeping an open mind

Jim was appointed President in June 2017. He served as Vice President and General Manager since July 2013, Vice President of Operations since 2006 and was Director of Manufacturing Operations and Engineering since 2001; prior to that he was the Manager of Engineering and Operations at Lifecore. Mr. Hall brings over 30 years of pharmaceutical and combination product manufacturing and development experience.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

Last week marked the return of DCAT in New York City. A prestigious event that’s open to companies engaged in the Biotech and Pharmaceutical manufacturing space…

With the massive return this year of events. Your host, Raman Sehgal, decided to shake things up this year and do things differently, taking your favourite life science podcast Molecule to market with him… Equipped with only a laptop and a microphone, he hit the event space in style and interviewed some great guests along the way.

Listen to a variety of select guests at the top of their field. 

• Yasmin Davoodi, Head Of Commercial at ramarketing

• Jon Lenihan, Head of Sales & Business Development, CDMO Business Unit Head at Emergent Biosolutions

• David Enloe, President and CEO of Societal™ CDMO (formerly Recro)

• Gil Roth, President, Pharma and Biopharma Outsourcing Association

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Magnus Gustafsson, formerly at the time of recording Head of Global Business Development now Chief Business Officer at Biovian.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Magnus, covering:

• The advantages and disadvantages of viral vector products, including the challenge of needing to balance cost with patient access.

• Insights into a CDMO with a 96% staff retention rate and an enviable NPS score.

• The ballooning opportunity that exists in the viral vector space but also the risk that potentially comes along with such a popular platform.

• What makes Finland and the Nordic region so special?

Magnus Gustafsson has worked in the biopharma manufacturing space for over 20 years. He holds an MSc in Biochemical Engineering, an MBA in Business Administration and a PhD in Medical Protein Science. Having worked for the likes of AZ, GE, Recipharm and Cobra Biologics, he has a track record of driving business with both commercial and strategic success combined with a customer-centric mindset. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Hanns-Christian Mahler CEO at ten23 health.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Hanns, covering:

• Transitioning from the structure and scale of Merck, Roche and Lonza into an entrepreneurial start-up CDMO leader.
• Having a business purpose focused on the triple-bottom line that is not just profit - patients, people and planet.
• Tips and insights of how a CDMO can play its part in encouraging sustainability, reducing environmental impact and managing footprints, across all levels.
• Insights into the opportunity and growth in small-scale sterile biologics, and some of the drivers behind these trends.
• Dr. Mahler is CEO & Board Member at ten23 health. He previously led the Drug Product Services (DPS) Business Unit at Lonza and worked in various leadership roles at Roche and Merck. He has an extensive expertise in formulation development, process development & validation, packaging/device development and integration, sterile manufacturing, and regulatory submissions.

With a Ph.D. in toxicology, he also serves as Editor for Pharmaceutical Research, Journal of Pharmaceutical Sciences, AAPS Open Journal, and PDA Journal of Pharmaceutical Sciences & Technology. He has published more than 120 manuscripts and is co-inventor of more than 50 patents.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with David Leitham, Senior Vice President and General Manager at Aspen Technology.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with David, covering:

• Why a transformative approach is now needed to better deal with new therapeutics and modalities.
• The pandemic as the inflexion point for companies in pharma to truly adapt technology and create a competitive advantage.
• How contract services organisations are driving change in the life science sector and why they could be the ‘lighthouse’ for others to follow.
• Being open to failure, embracing the wrong calls and treating every set back as a learning opportunity.

David leads the pharma business unit at AspenTech, defining solutions that best serve the needs of pharmaceutical manufacturers to accelerate digitalization in their environments.

Prior to AspenTech, David spent nearly 20 years with Thermo Fisher Scientific. 

He held multiple leadership positions, most recently as Vice President and General Manager responsible for a team of more than 500 people. In this role, he drove digital transformation efforts for multiple businesses within the company, while also integrating and harmonising product divisions for improved organisation and performance.

His previous roles include Glaxo SmithKline where he served as Vice President, Information Engineering, Technology and Architecture. David attended Penn State University where he holds a Master of Science degree in Software Engineering, and a Bachelor of Science degree in Aerospace Engineering.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jaqueline Escotero, Regional Vice President for Latin America at World Courier.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jaqueline, covering:

• The misconnections, characteristics and challenges of doing business in Latin America’s pharmaceutical sector.
• The immense complexity and level of responsibility involved in vaccine storage and distribution over the last year.
• Timeless lessons from a lifetime spent doing international business all over the world.
• A key trend that everyone in our sector needs to be prepared for in a post-pandemic world.

Jaqueline is responsible for the World Courier business in Latin America and is based in São Paulo, Brazil. She is an experienced executive, with 29 years of international experience in the healthcare industry, leading important roles in marketing, sales, training, government and external affairs, specialty logistics and customer service at major pharmaceutical and medical device companies. She holds an MBA in Strategic Marketing and Bachelor Degree in International Business. She is also the global Chairperson of WIN - “Women’s Impact Network” - at AmerisourceBergen, a global initiative, focused on over 40,000 employees.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Ross Burn, Chief Executive at CatSci.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ross, covering:

• Creating a successful business from an opportunistic AZ spin-out.
• Never being afraid to pivot in-line with the needs of the market and have big aims like becoming an innovative medicines development partner with a $1 billion valuation.
• The challenge of raising capital as an oversubscribed CRO with a 50% compound growth rate.

How the pandemic has helped put life sciences and pharma R&D on the map but also the work to be done to meet unmet needs.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

In this special bonus episode of Molecule to Market, our host discusses his very first book launch ‘The Floundering Founder’ which is now available on Amazon and Kindle. 

Whilst you know him as the host of Molecule to Market, Raman has built up an impressive career in marketing, leadership and sector disciplines over the past 20+ years working within the global pharmaceutical and biotech outsourcing sector. Over the past twelve months of that career, Raman has spent an hour each day working on his latest achievement: ‘The Floundering Founder.’

The Floundering Founder gives 24 lessons to refocus your business and better yourself.  

With quick, simple lessons, The Floundering Founder can help you re-engineer your business and your life for sustainable, long-term success.

In twenty-four bite-sized lessons that fit any schedule, you’ll learn to navigate forward with renewed intentionality and purpose.

Make no mistake, this book isn’t fictional. You will relive the close and personal revelations of starting and scaling a business and how ramarketing has grown to be one of the most fast-growing global marketing agencies. 

To purchase visit:

UK link is here

US link is here

We would love to hear what you think of the book! Please write us a review to let us know what you think in the review section.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Peter Soelkner, Managing Director at Vetter.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Peter, covering:

• The fascinating and humble origin story of one of the world’s most well respected sterile filling specialists.
• Peter’s journey of leading Vetter in becoming a $1bn, 5500 person family-owned CDMO...alongside a fellow Managing Director.
• How the DNA of a culture becomes a critical competent of global business growth and consistent client delivery.
• Key future industry trends, including the challenge of preparing for the ‘colourful scenery of biotechs in the next 10 years’ - meaning the need to have the flexibility to deal with ultra orphan drug products and high volume products needing high speed lines.

Peter Soelkner has been a Managing Director of Vetter Pharma-Fertigung GmbH & Co. KG since June 2008. In 2009, he was also appointed Managing Director of Vetter Pharma International GmbH, the company’s marketing and sales organization. Soelkner graduated from the University of Dortmund, Germany, in 1992 with a degree in chemical engineering and earned an MBA from Columbia University, New York, in 2001. Before joining Vetter, he held positions in Germany and North America at Sartorius AG and Sartorius North America Inc., in R&D, marketing, key account management, and general management roles. At Vetter, from 2003 to 2007, Soelkner managed the company’s key account program and global end-to-end supply chain. He left the company for a year to serve as Vice President of global key account management at Sartorius Stedim Biotech (USA) before returning to Vetter in 2008.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Bill Vincent, Founder and board chair at Genezen.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Bill, covering:

• The days when CGT therapies were viewed as just academic... then the events in 2012 that changed everything in the space
• How partnering with Indiana University for its vector capacity led to the creation of Genezen
• Building a team that had been trained really well... by his wife!
• Looking for a PE company that brings more than just a fat cheque
• What’s next for the CGT sector after an over-hyped few years of fundraises... and what areas could be hot in the future

Bill is the board chair of Genezen, a biotech contract manufacturer of viral vectors, cell manufacturing, and testing services. He founded the company fourteen years ago and grew it from his one-person operation to its current 60 employees with an outside investment of $45 million. He has spent the last 35 years working in the consumer products, pharma, and biotech sectors.

Prior to Genezen, Bill was President and CEO at Rimedion, a gene therapy company developing treatments for rare genetic disorders. He currently serves on the board of Cellular Engineering Technologies, a stem cell services company.

Bill discovered a passion for entrepreneurship through his exposure to new business development opportunities in a corporate setting. Upon completing his MBA at the University of Texas, he participated in a two-year executive development program with Philip Morris.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this special roundtable episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

Jean-Jacques Mondoloni, Managing Partner WOMBAT CAPITAL

Mark Quick, Executive Vice President Corporate Development at Recipharm

Gerry Cox, Vice President at Pace Life Sciences

Your host, Raman Sehgal, discusses M&A trends in the pharmaceutical and biotechnology supply chain, covering:

• What a real-life M&A deal in outsourcing looks like from the buyer, seller and advisor angle.
• How the dynamics of M&A have changed over the last decade given the fragmented marketplace alongside increased funding, PE-interest and a pandemic spotlight now on the sector.
• Dizzying multiples, the fight for assets and key factors driving deals and valuations in contract services.
• Predictions from the panel around the future of deal flow in the outsourcing space... will the current velocity continue?

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Michelle Duggan, Inward Investment Manager, Invest North East England.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Michelle, covering:

• Why is North East England becoming a UK hot spot for Health and Life Sciences.
• Collaborating and breaking down barriers to help create a super cluster of life sciences.
• The academic and industrial heartbeat that makes the region so attractive to CDMOs and major supply chain players.

Michelle Duggan has been an inward investment manager at invest North East England since January 2021. In 2016 to 2020 she was previously appointed as Partnership manager of Newcastle University where she was responsible for cultivating and maintaining relationships among business partners. 

Her devotion to the North East is unmatched across her extensive career. With her other previous position as economic advisor at North East Local Enterprise Partnership she helped place where businesses invest, grow and prosper - delivering more and better jobs for everyone.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Chris Eccles, Chief Executive Officer at ChargePoint Technology. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Chris, covering:

• The journey from a management buy-out (MBO) to running a £20m,100-person, global business.
• Benefit of investing in technology within sterile environments to avoid cross contamination and prevent expensive downtime.
• A perfect storm of market factors that are driving demand for ChargePoint and its products, including the explosion of facility investments in the CDMO space.
• The shift towards single use technologies yet the need to combat plastic usage. And how sustainability will become a core business issue and a major valuation metric for buyers.
• An inside look into the virtual process of ChargePoint’s recent acquisition by Arcline Investment Management and the dizzying level of buyers that were in the running for the fast-growing business.

Chris has managed the global business expansion of ChargePoint across all functions including offices based in the UK, Europe, America and Far East. His background in manufacturing management and precision engineering was instrumental in determining the strategy to outsource manufacturing through strategic acquisitions and equipment investments, including the investment in cleanroom technology and disposable manufacturing processes in 2019 and the managed recruitment of technical resources.

As CEO of ChargePoint, Chris has developed a strong positive culture within ChargePoint, focussed on honesty, integrity, and quality which is ultimately reflected in customer satisfaction, employee retention. And the recent successful acquisition of ChargePoint by Arcline Investment Management.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Go van Dam, CEO & Founder at TRACER.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Go, covering:

• The value of micro-dosing and fluorescent imaging in small patient populations at the preclinical proof of concept phase, and the benefits to investors, biotech and big pharma.
• The journey of stepping out of the operating theatre and into the boardroom. Taking an idea from the academic breeding ground and scaling into an industrial level so it has greater application.
• How the academia and industry ecosystem can collaborate, share and partner for the greater good.
• The need to observe, talk and learn from others. And it’s OK to copy and paste what you like in others.

Prof. Go van Dam is the CEO and Co-Founder of TRACER, a Clinical Research Organisation specialising in generating fast and accurate in-human data with nuclear and optical molecular imaging techniques, even before the classical Phase I-III studies. Go is seen as a pioneer in the optical imaging field with groundbreaking research to his name. 

Go originated as a surgeon oncologist and professor of Surgery at Groningen University. He trained at Harvard, the Mayo Clinic and NCI. Go executed and published the 1st in-human application of targeted fluorescence imaging in 2011 (Nature Medicine) and published more than 140 papers predominantly about clinical translation of innovative targeted optical molecular imaging. He currently focuses on utilising his validated optical imaging expertise in the life sciences industry to reduce R&D innovation costs, shorten time-to-market, and increased efficiency for innovative drug development.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Devendra Mishra, Executive Director and Founder at Bio Supply Management Alliance (BSMA).

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Devendra, covering:

• Being at the birth of biotech becoming a business and creating a network of 10k+ supply chain professionals.
• How we have just been through the most creative and productive period in healthcare in the last 100 years. Government bodies, private companies and academia collaborating to break down barriers and accelerate growth.
• The similarities of developing a movie and developing a new drug product. And what the life science supply chain can learn from digital collaboration and data analytics that occur in Hollywood.

Devendra is an internationally recognized authority on supply chain management thinking and practice. For two decades he has been committed to the adoption of disruptive technologies in media and entertainment as well as life sciences as an adjunct professor of Supply Chain Management at Pepperdine University.

Since 2004, the Mission of BSMA has been to advance the supply chain of Life Science through collaboration and adoption of technology. Positioned in the USA, Europe and India, its members are all the major biotech and pharma companies of the world.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at - zymewire.com 

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Daniel Hogan, External Manufacturing Team Lead for the Americas at Bayer Pharmaceuticals.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Daniel, covering:

• Managing a portfolio of 30-50 CMO partners across OSD, aerosols, topicals and liquids. And why due diligence and careful CMO selection is vital given its 10 x harder to exit a site.
• Some of the fundamental differences and similarities between sourcing as a big pharma and a small biotech.
• What good and bad relationships look like with an outsourced partner.
• The proliferation and availability of vendors in the outsourcing space. And why there is always room for CDMOs/CMOs with novel capabilities.
• Timeless advice for CDMOs/CMOs/CPOs in building relationships and revenue with big pharma.

With almost 20 years in the sector, Dan’s technical knowledge encompasses diverse pharmaceutical dosage forms with experience manufacturing and formulating a wide range of products for oral, topical, and parenteral administration. He thrives on contributing to complex products with the potential to cure people of disease, enabling them to lead lives of health and wellness.

Leading a team of experienced engineers responsible for the technology interface between Bayer and Contract Manufacturing Organizations (CMOs), Dan currently manages the manufacturing of a diverse dosage, multimillion-dollar product portfolio while providing guidance on activities such as process optimization, technology transfer from Bayer research and development to CMOs and validation of processes at commercial scale at various CMOs.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at - zymewire.com

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Grant Merrill President & CEO at AES Clean Technology.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Grant, covering:

• Becoming the leader of the business that he dreamt of representing.
• The need for cleanrooms to work in an invisible way as the most critical square footage at the core of the facility.
• Having to keep up with demand during the pandemic with the swelling production needed due to covid vaccines.
• The new therapeutic areas that are driving market growth and the need to let science flourish.
• Why the CMO space is poised for growth in both drug substance and drug product.
• The simple but magical abilities of being able to communicate and building personal relationships.

Grant Merrill has been involved with cleanroom design and construction for over 25 years. He earned his BS in Mechanical Engineering from Cornell University, and then immediately entered the world of critical facilities and the mechanical systems that support them. After a successful career in the industrial HVAC engineering business, Grant joined the AES team 20 years ago. Now as President & CEO, he leads multi-disciplinary teams to deliver complex cleanroom facilities to clients throughout the life science industry.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed. 

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at - zymewire.com

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Carl Turner, Vice President Supply Chain at Mayne Pharma.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Carl, covering:

• Managing 30+ CDMOs across several drug delivery systems and having the unique perspective of being on the buy CMO side, but having visibility of the CMO sell side.
• The 4 Cs that Carl looks for in sourcing, evaluating and selecting a new CMO partner. And what a great vendor relationship looks like
• The constant balancing act of risk mitigation and achieving economies of scale in using third party vendors.
• The impact of globalisation on product supply and the value of having plant-level contacts and communications.

Carl has almost three decades of experience in the pharmaceutical sector. A biologist by trade, he worked his way up the ranks at Abbot for 12 years in operations. He then made his way into planning and supply chain operations during 11 years with Hospira (became Pfizer). He has spent the rest of his career at Mayne Pharma helping the Australian-headquartered pharma company manage its complicated clinical and commercial global supply chain.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

In this special events-themed episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

• Samuel Thangiah, co-founder of Life Science Integrates
• Tara Dougal, Head Of Content & Insights for Pharma at Informa Markets
• Edward McNamara, Vice President of Innovation Banking - Life Sciences at Cambridge Trust and the Co-Founder of BioXchange

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology event scene with his three guests, covering:

• The impact on event organisers and the pivot required over the last 18 months including the birth of the smart/hybrid event model.
• The side effect benefits of virtual events including international reach and even better speakers.
• A look forward to what local, regional, national and international trade events may look like in the future. And, how you and your organisation should be thinking about, approaching and planning for events in 2022.

Samuel is Co-Founder and Executive Director of Life Science Integrates. Life Science Integrates produces the debate-led events shaping conversations in Pharma, BioTech and MedTech.

Tara is Head of Content and Insights for the Pharma Portfolio at Informa Markets, where she has worked since 2015. In this role, Tara leads the digital and live content strategy for CPhI Worldwide, Pharmapack Europe and CPhI North America.

Ed is Vice President of Innovation Banking at Cambridge Trust and has both a life sciences and banking background. Prior to joining Cambridge Trust, Ed worked on business development for Biotech Vendor Services. Ed also co-founded a very successful networking group, BioXchange

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Martino Picardo, Chairman at Discovery Park.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Martino, covering:

• His ‘three careers’ over the last few decades, mainly spent translating science into commercial entities that make a difference.
• Building Stevenage Bioscience Catalyst from the ground-up from the middle of the golden triangle through relationships, partnerships and networking.
• The ‘holy trilogy’ of building incubators from a blank sheet to successful, thriving communities.
• Creating a life science village from a transitioning Pfizer R&D site in the UK into an ecosystem with 160 companies.
• Never being a better time to work in life sciences and for entrepreneurs to thrive in the ecosystem.

Martino is Chairman of Discovery Park and an Independent Consultant. With a a PhD in Biochemistry, Martino spent almost a decade with Amersham International after his time in academia.

He was the first CEO of the Stevenage Bioscience

Catalyst an ambitious concept to develop an Incubator and Accelerator, which is now as world class Science Park.

A former Entrepreneur in Residence at UMIP, Manchester and with the NHS, Martino is also on Board of BIONOW, and is Chairman of VisusNano Ltd and Evidential Ltd.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Helen Shaw and Dan Henley, co-founders of VCTC.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Helen and Dan, covering:

• Exposing your team to everything, letting them feel the pressure... but always being there to help and guide
• The founding story of VCTC... and the fun and games of dividing responsibilities as co-founders
• How the frustrations of being a patient with an orphan disease shaped the ethos of VCTC
• The uptake of patient recruitment and retention in virtual and decentralized clinical trials
• Finding a powerful niche in the life sciences space to enable you to grow, globally

Helen and Dan are co-founders of the VCTC, a UK clinical trial site that specializes in delivering virtual and decentralized clinical trials.

Helen has fourteen years of clinical research experience spanning academia, clinical trial sites, biotech and CRO, with exposure across study management, medical writing, clinical science, and commercial roles.

Dan is a senior executive bringing 15 plus years of comprehensive achievements in predominantly commercial roles supporting biotechnology, pharma and life sciences companies, through their non-clinical, clinical and commercial journeys.

The VCTC is a UK-based clinical trial site that specializes in running patient-centric clinical trials. We bring virtual and decentralized clinical trials to participants in their own homes.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

After years of frustration with recruitment service providers in our space and seeing many of my CRO/CDMO connections miss their growth targets because their talent agenda just can’t keep up, I decided to create a talent sourcing solution for pharma & bio outsourcing. Proudly introducing, Lead Candidate.

The business has been founded purely to support ambitious, growing CROs, CDMOs and pharma service firms. Lead Candidate aims to help address many of the common issues we see guests talk about - attracting people into industry, improving diversity in our sector and simply being better prepared for growth.

For many years, I strongly believed there was a need for long-term, responsible, talent acquisition from people who genuinely understand the intricacies of our industry. And a firm that would also take responsibility for championing careers and treating people with respect. 

Whether you’re looking to build your team or find your next move, visit Lead Candidate and get in touch with the team.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug product and sterile injectables sector with Cory Lewis CEO and President, Founder at INCOG BioPharma Services.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Cory, covering:

• The incredible 10-year journey of Cook Pharmica from a burning cash turnaround challenge to a $950M acquisition by Catalent.
• Customer-centric lessons learned from the franchise business model that’s being adopted by a CDMO start-up.
• The continued growth of the sterile manufacturing space in North America and several growth drivers.
• Life as a founder of a CDMO start-up after 25+ years as a senior industry exec.

Cory has spent 25 years in the CDMO space. After a spell with Baxter, he served as vice president of business development and marketing for Cook Pharmica until its 2017 sale to Catalent for $950M. He has since founded INCOG, a start-up CDMO that is investing $60M to build its 90,000 square foot headquarters in Fishers, Indiana and hiring about 150 people by the end of 2024.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dr. Louise Duffy, Ph.D., SVP and Head of the Scientific Project Leaders at Abzena.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Louise, covering:

• Learnings for CDMOs after almost three decades spent with big pharma. 
• How to balance the juggling act between dealing with hundreds of projects, clients, and systems as a fast-growing large molecule CDMO.
• Why the speed of innovation has massively increased in pharma and biopharma over the last 10 years.
• Tips on how to improve your presence and move forward quicker as a female leader.
• The importance of closer-knit supply chains involving originators, CDMO, technology, equipment, and material providers in developing increasingly complex molecules.
• The trend towards customised molecules with exquisite targeting and greater government interest as consequence of Covid.

Dr. Louise Duffy is a Senior Executive with an extensive background in the global bio/pharmaceutical industry with experience in business development, strategy, R&D, operations, and supply chain. She has more than 30 years’ experience in the industry, including increasing responsibilities at GlaxoSmithKline and Janssen. With broad CMC and regulatory experience and specialist knowledge in personalised medicine, biochemical engineering, chemistry, and biological sciences Louise is SVP and Head of the Scientific Project Leaders at Abzena.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Sébastien Ribault, Vice President & Head of End to End CDMO Services, Process Solutions at Merck Life Science.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Sébastien, covering:

• The ever-changing world of biotech and how things talked about 20 years ago are now becoming a reality for many treatments. 
• Re-inventing the drug development process when faced with the 'Everest' of taking a covid treatment from bench to production in just nine months. 
• Learning to ask those around you: "If you could do things differently - what would you do?" as a way of unlocking innovation and challenging the norm.
• The wave of personalised medicines and treatments on the horizon and the need to develop the tools to bring down costs and make them more accessible.

With a PHD in Molecular & Cellular Biology, Sébastien has been in the biotech space for almost 25 years. He has spent the bulk of his career at Merck Life Science where he has progressed to the position of Head of End to End CDMO Services for Process Solutions.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! 

Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile, and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Vanessa Elharrar  PPD, VP, Vaccines Business Strategy Lead, at PPD Vaccine Clinical Development and Medical Affairs.  

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Vanessa, covering:  

• Being at the centre of vaccine development and patient distribution over the last year. And the global pandemic’s role as a day of reckoning for the sector to do things differently in terms of virtualisation of trials becoming the norm.
• How MRNA vaccines could be the key to helping in HIV research and supporting patients at risk of AIDS.
• Carving a career path aimed at making the biggest impact on the global patient population.
• The need to be better prepared for future pandemics in terms of better better disease surveillance and detection, but also stockpiling vital equipment and having local vaccine manufacturing capability.
• The increasing trend towards CDMOs and CROs merging to offer a complementary and unified offering to help clients reduce timelines.

An MD/Doctor by trade, Vanessa now leads early engagement with Vaccine sponsors and offers strategic guidance in the development and implementation of vaccine trials. Her areas of expertise include COVID-19 vaccine development and medical monitoring of vaccine studies and HIV biomedical prevention. She is Board Certified in Preventive Medicine and Public Health having completed a Masters in Public Health at The John Hopkins University. If that was not impressive enough, Vanessa is also fluent in French, Spanish and Hebrew.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with JaeB Kim, Managing Director at Samsung Biologics America.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with JaeB, covering:

• A year at one of the largest and fastest-growing CDMOs in the world.
• Growing a US presence within the thriving biopharma cluster in San Francisco Bay with ambitious plans for future expansion.
• The need for industry to ‘give’ in order to ‘take’ from innovation in academia, along with the pivotal role that collaboration has played during the pandemic.
• How Covid-19 has ‘tested the system’ from R&D to logistics and patient supply and how this will enable the sector to be better prepared for a more orchestrated response to future pandemics.

JaeB is a senior life sciences professional with 15 years of experience in biotech and biologics manufacturing. With an MBA and a PhD in Cancer Biology, he worked for PerkinElmer before joining global CDMO giant Samsung Biologics in 2020. JaeB is also an Adjunct Assistant Professor at Michigan State University.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Urvish Pandya, Managing Director at Allotrope Scientific Ltd.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Urvish, covering:

• The exponential growth of chemistry in India leading to the production of many fine Indian chemists all over the world.
• Honest advice on how to deal with being made redundant as a result of being caught in the crossfire of M&A in the outsourcing space.
• The role of guiding drug sponsors in finding the right CRO and CDMO match, then getting the best out of them as a partner.
• The need for more modular and flexible capabilities in later stages of the drug manufacturing process.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Andrew Moore, General Manager at Pfizer CentreOne.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Andrew, covering:

• The pride of being part of Pfizer in the last year and first-hand experience of working with CEO Albert Bourla.
• Lifelong leadership lessons learnt during eight years of military service in Iraq, where decisions cost lives.
• Being the only black guy in the room 99% of the time and the seriousness of being a black leader and the need to drive diversity for better business outcomes.
• Pushing yourself outside of your comfort zone by going from the corporate life to a ‘roll your sleeves up’ CEO at a university spin-out.

Andrew is an experienced healthcare leader and entrepreneur, who began his healthcare career in sales and marketing, including seven years at Pfizer. He has also held leadership roles Baxter, AmerisourceBergen and McKesson. Most recently Andrew was the CEO of AI start-up CogxVision before rejoining Pfizer. Prior to his professional career, Andrew served in the U.S. Army where he received multiple accolades, including the Bronze Star for his combat experience in Iraq Desert Storm.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tom Moody, Vice President of Technology Development and Commercialisation at Almac.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tom, covering:

• 20 years at Almac and being on a journey that has seen the company go from a few hundred staff to over 5500 people.
• The chemistry of today is not the chemistry of tomorrow, including the future impact of flow chemistry and the need to bring new technologies together.
• The importance of giving back to the community and inspiring the next generation of scientists.
• Reinventing yourself as a way to keep you on your toes

Prof. Tom Moody is the Vice President of Technology Development and Commercialisation at Almac Sciences. His work has earned him numerous accolades and he is co-author and author of over 60 publications and patents. He is a strategic leader and technical expert in chiral chemistry and biocatalysis with more than 20 years of extensive academic and industry experience.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Peter Bigelow President at xCell Strategic Consulting.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Peter, covering:

• The transition from being on the big pharma sponsor side at Pfizer to being head of one of the world’s biggest CDMOs.
• The challenging of adding a development capability to well-oiled manufacturing infrastructure and way of working.
• They key buying criteria emerging pharma considers when choose a CDMO.
• Increasing consolidation and fragmentation in today’s outsourcing sector due to continued market growth and the explosion of new technologies.

Pete is a very well respect industry leader having spent over 25 years in the global pharmaceutical manufacturing space. He was at Wyeth and then Pfizer for the best part of 15 years before becoming the interim CEO and President of North American operations at Patheon. He since moved into management consulting before establishing his own firm called xCell in 2014.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Bill Humphries, CEO at Alcami.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Bill, covering:

• The role managers, leaders, and mentors have played in shaping his illustrious career in dermatology
• The importance of ‘force multiply’ in getting results and accelerating growth
• Why, after a career spent on the drug sponsor side... he decided to switch to the CDMO services side
• How do the shifting sands in the sector provide a treasure trove of opportunities?

Bill Humphries, Alcami CEO, is an experienced leader in the life sciences industry, previously serving as CEO at Isosceles Pharmaceuticals, President and Group Company Chairman of Ortho-Dermatologics, CEO of Merz North America, President of Stiefel, a GSK Company and Vice President of US Skincare at Allergan Pharmaceuticals. 

Bill also served as Chairman of the Board at Clearside Biomedical, Executive Chairman of Strata Skin Sciences, and a member of the Board of Directors at Aclaris Therapeutics, PhaseBio Pharmaceuticals, SKNV, and Bryn Pharmaceuticals. Humphries’ academic credentials include a B.A. from Bucknell University and an MBA from Pepperdine University.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency that helps companies differentiate, get noticed, and grow in the life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Steve Ferguson, Chief Executive Officer at Medix Biochemica. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Steve, covering:

• The positive and negative impact of Covid-19 on the diagnostic sector. And the need for more spend on diagnostic sector moving forward.
• How his humble and grounded upbringing gave him an early respect for the strength of women and gender equality.
• Simply the importance of having fun, enjoying yourself and making a difference at work. Otherwise, what’s the point?
• The importance of creating visibility in a fragmented segment of the outsourcing space and then overlaying relevance to the buyer.

With around 25 years’ experience in the life science sector, Steve has worked for the likes of Lundbeck and Thermo Fisher before joining Medix Biochemica at the CEO. He is an expert in the pharma and diagnostic space and well-respected industry leader.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Archie Lovatt Life Sciences Biosafety Scientific Director at SGS.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Archie, covering:

• Being motivated by saving lives and seeing your contribution make a real impact on the world. Following your heart and not chasing the money.
• Seeing Covid-19 drugs developed in a parallel rather than sequential way, helping accelerate the process while not compromising on safety.
• Being acquired by SGS yet maintaining the entrepreneurial spirit to explore and innovate.
• The long term value to patients of now having more platform technologies and a greater operational infrastructure to deal with disease areas.

Archie is a vaccine, gene and cell therapy biosafety testing expert. He graduated with a PhD in molecular microbiology and has been in the industry for the best part of 30 years. During this time, he founded a CRO called Vitrology, which was then acquired by SGS in 2012 and has since served on the board as Scientific Operations Director. He was also voted into the top 100 most influential people in human medicine development and manufacture.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jeff Dill, CEO at Vynamic.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jeff, covering:·    

• How to create, document, grow and internationally scale an incredible business culture.
• The shift towards greater industry collaboration as an important step for quicker drug approvals in the future.
• Servant leadership philosophy - to listen, be empathetic and enable.
• The drive and transparency needed to create a more diverse and inclusive workforce.

Jeff boasts over 20 years’ experience in the healthcare consulting world. Previously at Accenture, Jeff joined healthcare industry management consulting firm Vynamic in 2005, he has been there ever since and is now the CEO.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.